cadonilimab + bevacizumab + docetaxel

This is a combination regimen consisting of three drugs: - **Cadonilimab** is a bispecific monoclonal antibody targeting both PD-1 and CTLA-4 immune checkpoints. It is designed to enhance anti-tumor immune responses by blocking two key inhibitory pathways in T cells. - **Bevacizumab** is a recombinant humanized monoclonal IgG1 antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby preventing tumor angiogenesis and starving tumors of their blood supply[3][4][5]. - **Docetaxel** is a cytotoxic small molecule chemotherapy agent from the taxane class that stabilizes microtubules and prevents cell division. This combination aims to leverage immunotherapy (cadonilimab), antiangiogenic therapy (bevacizumab), and cytotoxic chemotherapy (docetaxel) for synergistic antitumor effects. The regimen may be under investigation for advanced or metastatic cancers, such as non-small cell lung cancer or other solid tumors.